Savara

SVRAPhase 3

Savara is dedicated to developing and commercializing novel therapies for rare respiratory conditions with high unmet medical need. Its core asset is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), targeting the underlying immune dysfunction in aPAP. The company's strategy centers on advancing its late-stage candidate through regulatory approval while exploring its platform's potential in other orphan lung diseases. Savara operates as a lean, focused organization with significant clinical and regulatory expertise.

Market Cap

$1.0B

Employees

50-100

Focus

Biotech

SVRA · Stock Price

USD 4.96+3.73 (+303.25%)

Historical price data

AI Company Overview

Technology Platform

Inhaled delivery of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) via a proprietary nebulizer system to target immune dysfunction directly in the lungs.

Pipeline Snapshot

12 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
Molgramostim	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3
Molgramostim	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3
Molgramostim + Placebo + Molgramostim Open-label	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3
Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation...	MRSA	Phase 3
Inhaled molgramostim + Antimycobacterial regimen	Mycobacterium Infections, Nontuberculous	Phase 2

Funding History

Total raised: $175M

PIPE$75MRA Capital ManagementMar 15, 2021

IPO$60MUndisclosedJun 30, 2017

Series B$25MUndisclosedJun 15, 2010

Series A$15MUndisclosedJun 15, 2007

Opportunities

Approval of molgramostim for aPAP would unlock a monopoly position in a high-need orphan market.

Success could enable label expansion into other GM-CSF-deficient respiratory conditions or exploration of the inhaled platform for different therapeutic proteins.

Risk Factors

The company faces binary clinical risk from its single pivotal Phase 3 trial (IMPALA 2).

Regulatory hurdles, commercialization challenges as a first-time launcher, and potential future competition are significant risks to its valuation and viability.

Competitive Landscape

Primary competition is the invasive standard of care, whole lung lavage. Savara's molgramostim is the most advanced pharmacologic candidate, with a significant first-mover advantage and potential for orphan drug exclusivity, creating a high barrier to entry.

Publications

Pipeline